Y-mAbs Therapeutics Inc. (YMAB)
Y-mAbs Therapeutics Statistics
Share Statistics
Y-mAbs Therapeutics has 44.79M shares outstanding. The number of shares has increased by 2.31% in one year.
| Shares Outstanding | 44.79M |
| Shares Change (YoY) | 2.31% |
| Shares Change (QoQ) | 0.49% |
| Owned by Institutions (%) | 57.68% |
| Shares Floating | 34.11M |
| Failed to Deliver (FTD) Shares | 1.7K |
| FTD / Avg. Volume | 0.4% |
Short Selling Information
The latest short interest is 3.74M, so 8.35% of the outstanding shares have been sold short.
| Short Interest | 3.74M |
| Short % of Shares Out | 8.35% |
| Short % of Float | 10.11% |
| Short Ratio (days to cover) | 8.72 |
Valuation Ratios
The PE ratio is -13.89 and the forward PE ratio is -11.65. Y-mAbs Therapeutics's PEG ratio is 0.18.
| PE Ratio | -13.89 |
| Forward PE | -11.65 |
| PS Ratio | 3.51 |
| Forward PS | 1.9 |
| PB Ratio | 2.95 |
| P/FCF Ratio | -10.93 |
| PEG Ratio | 0.18 |
Enterprise Valuation
Y-mAbs Therapeutics Inc. has an Enterprise Value (EV) of 220.44M.
| EV / Earnings | -10.29 |
| EV / Sales | 2.6 |
| EV / EBITDA | -8.84 |
| EV / EBIT | -8.59 |
| EV / FCF | -8.1 |
Financial Position
The company has a current ratio of 5.52, with a Debt / Equity ratio of 0.01.
| Current Ratio | 5.52 |
| Quick Ratio | 5.27 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 1.39 |
| Cash Flow / Debt | -19.19 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.21% and return on capital (ROIC) is -25.74%.
| Return on Equity (ROE) | -0.21% |
| Return on Assets (ROA) | -0.17% |
| Return on Capital (ROIC) | -25.74% |
| Revenue Per Employee | $848,190 |
| Profits Per Employee | $-214,270 |
| Employee Count | 100 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 2.25 |
Taxes
| Income Tax | 561K |
| Effective Tax Rate | -0.03 |
Stock Price Statistics
The stock price has increased by -70.25% in the last 52 weeks. The beta is 0.67, so Y-mAbs Therapeutics's price volatility has been higher than the market average.
| Beta | 0.67 |
| 52-Week Price Change | -70.25% |
| 50-Day Moving Average | 6.77 |
| 200-Day Moving Average | 11.18 |
| Relative Strength Index (RSI) | 35.16 |
| Average Volume (20 Days) | 423.25K |
Income Statement
In the last 12 months, Y-mAbs Therapeutics had revenue of 84.82M and earned -21.43M in profits. Earnings per share was -0.49.
| Revenue | 84.82M |
| Gross Profit | 73.4M |
| Operating Income | -25.67M |
| Net Income | -21.43M |
| EBITDA | -24.94M |
| EBIT | -25.67M |
| Earnings Per Share (EPS) | -0.49 |
Balance Sheet
The company has 78.64M in cash and 1.42M in debt, giving a net cash position of 77.22M.
| Cash & Cash Equivalents | 78.64M |
| Total Debt | 1.42M |
| Net Cash | 77.22M |
| Retained Earnings | -457.47M |
| Total Assets | 120.92M |
| Working Capital | 73.77M |
Cash Flow
In the last 12 months, operating cash flow was -27.23M and capital expenditures 0, giving a free cash flow of -27.23M.
| Operating Cash Flow | -27.23M |
| Capital Expenditures | 0 |
| Free Cash Flow | -27.23M |
| FCF Per Share | -0.62 |
Margins
Gross margin is 86.54%, with operating and profit margins of -30.27% and -25.26%.
| Gross Margin | 86.54% |
| Operating Margin | -30.27% |
| Pretax Margin | -24.6% |
| Profit Margin | -25.26% |
| EBITDA Margin | -29.4% |
| EBIT Margin | -30.27% |
| FCF Margin | -32.11% |
Dividends & Yields
YMAB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -8.81% |
| FCF Yield | -10.94% |
Analyst Forecast
The average price target for YMAB is $23, which is 313.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $23 |
| Price Target Difference | 313.7% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
Scores
| Altman Z-Score | 0.29 |
| Piotroski F-Score | 2 |